Literature DB >> 18664987

Review of HIV antiretroviral drug resistance.

Tempe K Chen1, Grace M Aldrovandi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18664987      PMCID： PMC3909718          DOI： 10.1097/INF.0b013e3181846e2e

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  12 in total

Review 1.  International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations.

Authors:  L Demeter; R Haubrich
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

2.  Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes.

Authors:  Niko Beerenwinkel; Martin Däumer; Mark Oette; Klaus Korn; Daniel Hoffmann; Rolf Kaiser; Thomas Lengauer; Joachim Selbig; Hauke Walter
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

3.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.

Authors:  Rolando M Viani; Ligia Peralta; Grace Aldrovandi; Bill G Kapogiannis; Rick Mitchell; Stephen A Spector; Yolanda S Lie; Jodi M Weidler; Michael P Bates; Nancy Liu; Craig M Wilson
Journal:  J Infect Dis       Date:  2006-10-20       Impact factor: 5.226

4.  Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.

Authors:  Franco Maggiolo; Laura Ravasio; Diego Ripamonti; Giampietro Gregis; Giampaolo Quinzan; Claudio Arici; Monica Airoldi; Fredy Suter
Journal:  Clin Infect Dis       Date:  2004-12-06       Impact factor: 9.079

5.  HIV resistance: frequency, testing, mechanisms.

Authors:  Daniel R Kuritzkes
Journal:  Top HIV Med       Date:  2007 Nov-Dec

6.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

7.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

Authors:  Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; Jose M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; Stefano Vella; Patrick G Yeni; Paul A Volberding
Journal:  JAMA       Date:  2006-08-16       Impact factor: 56.272

8.  Web resources for HIV type 1 genotypic-resistance test interpretation.

Authors:  Tommy F Liu; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2006-04-28       Impact factor: 9.079

9.  HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.

Authors:  S L Welles; J Pitt; R Colgrove; K McIntosh; P H Chung; A Colson; S Lockman; M G Fowler; C Hanson; S Landesman; J Moye; K C Rich; C Zorrilla; A J Japour
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

10.  Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.

Authors:  Constance Delaugerre; Josiane Warszawski; Marie-Laure Chaix; Florence Veber; Eugenia Macassa; Florence Buseyne; Christine Rouzioux; Stéphane Blanche
Journal:  J Med Virol       Date:  2007-09       Impact factor: 2.327
View more
  10 in total

1.  Analytical and biological considerations in the measurement of cell-associated CCR5 and CXCR4 mRNA and protein.

Authors:  D E Campbell; J P Lai; N B Tustin; E Riedel; R Tustin; J Taylor; J Murray; S D Douglas
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

2.  Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.

Authors:  M Tozammel Hoque; Olena Kis; María F De Rosa; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

3.  Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.

Authors:  J-H Lee; A Hachiya; S-K Shin; J Lee; H Gatanaga; S Oka; K A Kirby; Y T Ong; S G Sarafianos; W R Folk; W Yoo; S P Hong; S-O Kim
Journal:  Clin Microbiol Infect       Date:  2013-03-11       Impact factor: 8.067

4.  Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.

Authors:  Emma Andrews; Paul Glue; Juanzhi Fang; Penelope Crownover; Randall Tressler; Bharat Damle
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

5.  Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.

Authors:  Orit Wolstein; Maureen Boyd; Michelle Millington; Helen Impey; Joshua Boyer; Annett Howe; Frederic Delebecque; Kenneth Cornetta; Michael Rothe; Christopher Baum; Tamara Nicolson; Rachel Koldej; Jane Zhang; Naomi Keech; Joanna Camba Colón; Louis Breton; Jeffrey Bartlett; Dong Sung An; Irvin Sy Chen; Bryan Burke; Geoff P Symonds
Journal:  Mol Ther Methods Clin Dev       Date:  2014-02-12       Impact factor: 6.698

6.  Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.

Authors:  Dwight E Yin; Christina Ludema; Stephen R Cole; Carol E Golin; William C Miller; Meredith G Warshaw; Ross E McKinney
Journal:  PLoS One       Date:  2020-11-23       Impact factor: 3.240

7.  Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

Authors:  Michael Neely; Andrea Kovacs
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

8.  Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.

Authors:  Raffaella Rosso; C Bernardini; B Bruzzone; G Secondo; G Icardi; C Viscoli; A Di Biagio
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

9.  The distribution of CTL epitopes in HIV-1 appears to be random, and similar to that of other proteomes.

Authors:  Boris V Schmid; Can Keşmir; Rob J de Boer
Journal:  BMC Evol Biol       Date:  2009-08-04       Impact factor: 3.260

10.  Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.

Authors:  Sami Hussain Al Hajjar; Husn Frayha; Sahar Althawadi
Journal:  Ann Saudi Med       Date:  2012 Nov-Dec       Impact factor: 1.526
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.